» Articles » PMID: 32684930

Pathogenesis, Assessments, and Management of Chemotherapy-Related Cognitive Impairment (CRCI): An Updated Literature Review

Overview
Journal J Oncol
Specialty Oncology
Date 2020 Jul 21
PMID 32684930
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

There are various cancer treatments at present, and chemotherapy is one of the main methods. Chemotherapy-related cognitive impairment (CRCI), as one of the side effects of chemotherapy, has gradually attracted the attention of more and more researchers. CRCI has been verified by subjective reports and objective neuropsychological tests so far. But oncologists' understanding of it and its treatments are still incomplete. In this review, we mainly give a comprehensive overview of the mechanism of CRCI, then describe a variety of evaluation methods, and finally summarize the treatment approaches under current medical conditions and compare it with an excellent article published in 2015 with the aim of providing directions for future research and better understanding of CRCI for clinicians.

Citing Articles

Advances in risk prediction models for cancer-related cognitive impairment.

Duan R, Wen Z, Zhang T, Liu J, Feng T, Ren T Clin Exp Med. 2025; 25(1):74.

PMID: 40047952 PMC: 11885319. DOI: 10.1007/s10238-025-01590-6.


Efficacy of acupuncture in treating chemotherapy-related cognitive impairment in breast cancer patients: A systematic review and meta-analysis protocol.

Liu L, Meng Z, Yan J PLoS One. 2025; 20(2):e0318984.

PMID: 39913618 PMC: 11801641. DOI: 10.1371/journal.pone.0318984.


Feasibility and Preliminary Effects of Acupuncture for Cognitive Dysfunction in Diverse Cancer Survivors: A Pilot, Randomized, Placebo-Controlled Trial.

Li X, Lampson K, Ahles T, Root J, Li Q, Li Y Curr Oncol. 2025; 32(1).

PMID: 39851943 PMC: 11763785. DOI: 10.3390/curroncol32010027.


Exercise as a Therapeutic Strategy to Improve Cerebrovascular Function and Cognition in Breast Cancer Survivors: A Scoping Review.

Downs T, Whiteside E, Denham J, Mills D, Bliss E J Clin Med. 2025; 13(24).

PMID: 39768764 PMC: 11678850. DOI: 10.3390/jcm13247841.


Characterization of cancer survivors clustered by subjective and objective cognitive function scores.

Goto T, Saligan L, Juneau P, Gonsalves S, Rio C, Graves L Cancer Med. 2024; 13(12):e7255.

PMID: 39185749 PMC: 11192644. DOI: 10.1002/cam4.7255.


References
1.
Reinvang I, Espeseth T, Westlye L . APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. Neurosci Biobehav Rev. 2013; 37(8):1322-35. DOI: 10.1016/j.neubiorev.2013.05.006. View

2.
Cheng H, Li W, Gan C, Zhang B, Jia Q, Wang K . The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am J Transl Res. 2016; 8(11):5087-5097. PMC: 5126352. View

3.
Oh B, Butow P, Mullan B, Clarke S, Beale P, Pavlakis N . Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer. 2011; 20(6):1235-42. DOI: 10.1007/s00520-011-1209-6. View

4.
Lower E, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z . Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009; 38(5):650-62. DOI: 10.1016/j.jpainsymman.2009.03.011. View

5.
Konat G, Kraszpulski M, James I, Zhang H, Abraham J . Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis. 2008; 23(3):325-33. DOI: 10.1007/s11011-008-9100-y. View